Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.Image by OpenClipart-Vectors on Pixabay
The Federal Trade Commission is challenging the $1.2 billion-merger between Illumina and PacificBio (PacBio). The agency says Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat.
Boston Scientific snagged FDA clearance to sell its Exalt-D single-use duodenoscope in the United States to provide visualization and access to the upper gastrointestinal (GI) tract to treat bile duct disorders and other upper GI problems. The Exalt-D is the first fully disposable duodenoscope to reach the market, which is seen as a huge win for patient safety because contamination on duodenoscopes after reprocessing has been such a major concern.
Tandem Diabetes has won a major nod from FDA that has the potential to advance its partnership with DexCom. The company received clearance for the t:slim X2 insulin pump with Control-IQ technology, which integrates with DexCom's G6 continuous glucose monitoring (CGM) sensor. The pump uses the DexCom G6 CGM sensor values to forecast glucose levels and adjust insulin delivery to ensure the prevention of erratic highs and lows.